Share on StockTwits

Acorda Therapeutics (NASDAQ:ACOR) Insider Jane Wasman sold 14,923 shares of the company’s stock on the open market in a transaction dated Wednesday, August 27th. The stock was sold at an average price of $33.00, for a total transaction of $492,459.00. Following the completion of the transaction, the insider now directly owns 105,284 shares of the company’s stock, valued at approximately $3,474,372. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Stifel Nicolaus initiated coverage on shares of Acorda Therapeutics in a research note on Tuesday, August 19th. They set a “buy” rating and a $47.00 price target on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of Acorda Therapeutics in a research note on Monday, August 4th. They now have a $30.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Acorda Therapeutics has a consensus rating of “Hold” and a consensus price target of $37.75.

Shares of Acorda Therapeutics (NASDAQ:ACOR) traded up 0.19% on Friday, hitting $32.35. The stock had a trading volume of 24,408 shares. Acorda Therapeutics has a 1-year low of $27.51 and a 1-year high of $39.95. The stock has a 50-day moving average of $30.57 and a 200-day moving average of $33.73. The company has a market cap of $1.328 billion and a P/E ratio of 72.24.

Acorda Therapeutics (NASDAQ:ACOR) last released its earnings data on Thursday, July 31st. The company reported $0.42 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.15 by $0.27. The company had revenue of $97.13 million for the quarter, compared to the consensus estimate of $91.40 million. During the same quarter in the prior year, the company posted $0.34 earnings per share. The company’s quarterly revenue was up 11.5% on a year-over-year basis. Analysts expect that Acorda Therapeutics will post $0.22 EPS for the current fiscal year.

Acorda Therapeutics, Inc (NASDAQ:ACOR) is a commercial-stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.